Audentes Therapeutics (BOLD) Tops Q1 EPS by 173c

Audentes Therapeutics (NASDAQ: BOLD) reported Q1 EPS of $0.71, $1.73 better than the analyst estimate of ($1.02).

For earnings history and earnings-related data on Audentes Therapeutics (BOLD) click here.

You May Also Be Interested In

• Alphabet Sees FY26 Capex $195B To $205B, Saw $180B To $190B
• MindWalk (HYFT) Misses Q4 EPS by 8c
• Es Bancshares, Inc. (ESBS) Tops Q2 EPS by 13c